Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

Citation

• Jotte, R., Von Pawel, J., Spigel, D. R., Socinski, M. A., O'Brien, M., Paschold, E. H., . . . Renschler, M. F. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology, 29(15_suppl), 7000. doi:10.1200/jco.2011.29.15_suppl.7000

Digital Object Identifier (doi)

• 10.1200/jco.2011.29.15_suppl.7000

Web Of Science Accession Number

Start Page

• 7000

End Page

• 7000

Volume

• 29

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2011

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Jotte, R., Von Pawel, J., Spigel, D. R., Socinski, M. A., O'Brien, M., Paschold, E. H., . . . Renschler, M. F. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology, 29(15_suppl), 7000. doi:10.1200/jco.2011.29.15_suppl.7000

Digital Object Identifier (doi)

• 10.1200/jco.2011.29.15_suppl.7000

Web Of Science Accession Number

Start Page

• 7000

End Page

• 7000

Volume

• 29

Issue

• 15_suppl

Place Of Publication